about
Thoracic Malignancies and Pulmonary Nodules in Patients under Evaluation for Transcatheter Aortic Valve Implantation (TAVI): Incidence, Follow Up and Possible Impact on Treatment Decision.Blood group antigen A type 3 expression is a favorable prognostic factor in advanced NSCLC.PD-1 targeted Immunotherapy as first-line therapy for advanced non-small-cell lung cancer patients.Prostate specific membrane antigen (PSMA) expression in non-small cell lung cancer.Progressive histoplasmosis with hemophagocytic lymphohistiocytosis and epithelioid cell granulomatosis: A case report and review of the literature.Progressive Multifocal Leukoencephalopathy after Ibrutinib Therapy for Chronic Lymphocytic Leukemia.Rhesus CE expression on patient red blood cells is an independent prognostic factor for adenocarcinoma of the lung.Future Options of Molecular-Targeted Therapy in Small Cell Lung Cancer.Nivolumab in a patient with refractory Hodgkin's lymphoma after allogeneic stem cell transplantation90 Y-ibritumomab-tiuxetan as a therapeutic alternative for follicular lymphoma (FL): A single-center experienceSoluble Triggering Receptor Expressed on Myeloid Cells 1 in lung cancerBlood clot removal by cryoextraction in critically ill patients with pulmonary hemorrhagePrognostic impact of CD34 and SMA in cancer-associated fibroblasts in stage I-III NSCLCNoncaseating granulomatous diseases in germ cell cancer patients-A single-center experienceAlpha-1 Antitrypsin Deficiency and Pulmonary Morbidity in Patients with Primary Immunodeficiency Disease: A Single-Center Experience
P50
Q36895846-A014837A-5C06-4755-839F-2E102FE3EA4AQ40099128-09D41759-021B-453E-A6E5-1DADC9EF9588Q42354900-92D3680D-BB2F-4FC1-8DB2-7AE112DB6368Q47174885-D3FDC768-F27E-45CF-B15D-C7B4F1C629CFQ47813445-FBFE594F-DDBE-4F50-8763-C6005D4487EBQ50351525-B002686A-02E3-452B-A6C5-73183CDC73A0Q54301102-05AA53FB-3204-4C6D-9A6D-C9A27A980144Q64971959-8E652FC3-3A78-40BC-A074-94664B36FB81Q86654387-2618CBAA-3FD1-4025-BDC0-F3C98066BD4FQ89546279-2F57C30E-DBB5-46E4-ACA4-72B169AA5767Q90294701-3C79A9CA-AFA3-4516-8C49-B2458708225DQ91318258-04E71ADC-0F02-48F9-87F2-CAAA81AE0EC7Q91418047-8FFA6CB4-FFBD-41E4-88FB-8C71F0F4EA54Q91750145-B66F754C-087B-4BE7-ACD2-412BCBC712A9Q96606749-E1A263E3-05E3-4A29-BD25-282234F37A28
P50
description
researcher ORCID ID = 0000-0002-1644-3573
@en
wetenschapper
@nl
name
Arik Bernard Schulze
@ast
Arik Bernard Schulze
@en
Arik Bernard Schulze
@es
Arik Bernard Schulze
@nl
type
label
Arik Bernard Schulze
@ast
Arik Bernard Schulze
@en
Arik Bernard Schulze
@es
Arik Bernard Schulze
@nl
prefLabel
Arik Bernard Schulze
@ast
Arik Bernard Schulze
@en
Arik Bernard Schulze
@es
Arik Bernard Schulze
@nl
P106
P214
694145910087327021711
P31
P496
0000-0002-1644-3573
P7859
viaf-694145910087327021711